Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab

Tania Jain, Jisha John, Aditya Kotecha, Abhinav Deol, Tanaz Saliminia, Sanjay Revankar, Pranatharthi Chandrasekar

Research output: Contribution to journalArticle

Abstract

The incidence of cytomegalovirus (CMV) reactivation/disease after autologous stem cell transplant (ASCT) is much lower than that after allogeneic stem cell transplantation. With the recent use of rituximab during cancer chemotherapy or conditioning regimens prior to transplantation, there has been an increasing concern of opportunistic infections including CMV. In the present study, we reviewed the patients undergoing ASCT from December 2007 to December 2013 to identify those developing CMV reactivation/disease. Out of the 978 patients who underwent ASCT at the Karmanos Cancer Institute, 239 patients were tested for symptomatic CMV reactivation based on clinical suspicion. Of the tested patients, 7/239 (2.9 %) were documented to have CMV reactivation within 90 days of ASCT. The median time to develop CMV viremia was 32 days from transplantation. Of the 239 patients tested, CMV viremia was detected in 3 out of 72 patients who received rituximab as compared to 4 out of 167 patients who did not. Three of these seven viremic patients were treated with anti-viral drugs; viremia resolved in all patients at a median of 24 days. Three patients were found to develop other bacterial and/or fungal infections following CMV viremia. Two of the seven patients died during 1-year follow-up, due to primary disease progression or Candida sepsis. None of the patients developed proven tissue-invasive CMV disease. The study did not evaluate the incidence of asymptomatic CMV infection/reactivation. Despite prior publications based on limited data, rituximab does not appear to contribute to an increased frequency of symptomatic CMV reactivation following ASCT.

Original languageEnglish (US)
Pages (from-to)1323-1327
Number of pages5
JournalAnnals of hematology
Volume95
Issue number8
DOIs
StatePublished - Aug 1 2016
Externally publishedYes

Fingerprint

Cytomegalovirus Infections
Cytomegalovirus
Stem Cells
Transplants
Viremia
Rituximab
Transplant Recipients
Transplantation
Asymptomatic Infections
Mycoses
Incidence
Opportunistic Infections
Stem Cell Transplantation
Candida
Bacterial Infections
Disease Progression
Publications
Neoplasms
Sepsis

Keywords

  • Autologous stem cell transplant
  • Cytomegalovirus infection
  • Rituximab

ASJC Scopus subject areas

  • Hematology

Cite this

Jain, T., John, J., Kotecha, A., Deol, A., Saliminia, T., Revankar, S., & Chandrasekar, P. (2016). Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab. Annals of hematology, 95(8), 1323-1327. https://doi.org/10.1007/s00277-016-2700-4

Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab. / Jain, Tania; John, Jisha; Kotecha, Aditya; Deol, Abhinav; Saliminia, Tanaz; Revankar, Sanjay; Chandrasekar, Pranatharthi.

In: Annals of hematology, Vol. 95, No. 8, 01.08.2016, p. 1323-1327.

Research output: Contribution to journalArticle

Jain, T, John, J, Kotecha, A, Deol, A, Saliminia, T, Revankar, S & Chandrasekar, P 2016, 'Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab', Annals of hematology, vol. 95, no. 8, pp. 1323-1327. https://doi.org/10.1007/s00277-016-2700-4
Jain, Tania ; John, Jisha ; Kotecha, Aditya ; Deol, Abhinav ; Saliminia, Tanaz ; Revankar, Sanjay ; Chandrasekar, Pranatharthi. / Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab. In: Annals of hematology. 2016 ; Vol. 95, No. 8. pp. 1323-1327.
@article{cd4f1c30a71d4e6294bc2443c78fe57c,
title = "Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab",
abstract = "The incidence of cytomegalovirus (CMV) reactivation/disease after autologous stem cell transplant (ASCT) is much lower than that after allogeneic stem cell transplantation. With the recent use of rituximab during cancer chemotherapy or conditioning regimens prior to transplantation, there has been an increasing concern of opportunistic infections including CMV. In the present study, we reviewed the patients undergoing ASCT from December 2007 to December 2013 to identify those developing CMV reactivation/disease. Out of the 978 patients who underwent ASCT at the Karmanos Cancer Institute, 239 patients were tested for symptomatic CMV reactivation based on clinical suspicion. Of the tested patients, 7/239 (2.9 {\%}) were documented to have CMV reactivation within 90 days of ASCT. The median time to develop CMV viremia was 32 days from transplantation. Of the 239 patients tested, CMV viremia was detected in 3 out of 72 patients who received rituximab as compared to 4 out of 167 patients who did not. Three of these seven viremic patients were treated with anti-viral drugs; viremia resolved in all patients at a median of 24 days. Three patients were found to develop other bacterial and/or fungal infections following CMV viremia. Two of the seven patients died during 1-year follow-up, due to primary disease progression or Candida sepsis. None of the patients developed proven tissue-invasive CMV disease. The study did not evaluate the incidence of asymptomatic CMV infection/reactivation. Despite prior publications based on limited data, rituximab does not appear to contribute to an increased frequency of symptomatic CMV reactivation following ASCT.",
keywords = "Autologous stem cell transplant, Cytomegalovirus infection, Rituximab",
author = "Tania Jain and Jisha John and Aditya Kotecha and Abhinav Deol and Tanaz Saliminia and Sanjay Revankar and Pranatharthi Chandrasekar",
year = "2016",
month = "8",
day = "1",
doi = "10.1007/s00277-016-2700-4",
language = "English (US)",
volume = "95",
pages = "1323--1327",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab

AU - Jain, Tania

AU - John, Jisha

AU - Kotecha, Aditya

AU - Deol, Abhinav

AU - Saliminia, Tanaz

AU - Revankar, Sanjay

AU - Chandrasekar, Pranatharthi

PY - 2016/8/1

Y1 - 2016/8/1

N2 - The incidence of cytomegalovirus (CMV) reactivation/disease after autologous stem cell transplant (ASCT) is much lower than that after allogeneic stem cell transplantation. With the recent use of rituximab during cancer chemotherapy or conditioning regimens prior to transplantation, there has been an increasing concern of opportunistic infections including CMV. In the present study, we reviewed the patients undergoing ASCT from December 2007 to December 2013 to identify those developing CMV reactivation/disease. Out of the 978 patients who underwent ASCT at the Karmanos Cancer Institute, 239 patients were tested for symptomatic CMV reactivation based on clinical suspicion. Of the tested patients, 7/239 (2.9 %) were documented to have CMV reactivation within 90 days of ASCT. The median time to develop CMV viremia was 32 days from transplantation. Of the 239 patients tested, CMV viremia was detected in 3 out of 72 patients who received rituximab as compared to 4 out of 167 patients who did not. Three of these seven viremic patients were treated with anti-viral drugs; viremia resolved in all patients at a median of 24 days. Three patients were found to develop other bacterial and/or fungal infections following CMV viremia. Two of the seven patients died during 1-year follow-up, due to primary disease progression or Candida sepsis. None of the patients developed proven tissue-invasive CMV disease. The study did not evaluate the incidence of asymptomatic CMV infection/reactivation. Despite prior publications based on limited data, rituximab does not appear to contribute to an increased frequency of symptomatic CMV reactivation following ASCT.

AB - The incidence of cytomegalovirus (CMV) reactivation/disease after autologous stem cell transplant (ASCT) is much lower than that after allogeneic stem cell transplantation. With the recent use of rituximab during cancer chemotherapy or conditioning regimens prior to transplantation, there has been an increasing concern of opportunistic infections including CMV. In the present study, we reviewed the patients undergoing ASCT from December 2007 to December 2013 to identify those developing CMV reactivation/disease. Out of the 978 patients who underwent ASCT at the Karmanos Cancer Institute, 239 patients were tested for symptomatic CMV reactivation based on clinical suspicion. Of the tested patients, 7/239 (2.9 %) were documented to have CMV reactivation within 90 days of ASCT. The median time to develop CMV viremia was 32 days from transplantation. Of the 239 patients tested, CMV viremia was detected in 3 out of 72 patients who received rituximab as compared to 4 out of 167 patients who did not. Three of these seven viremic patients were treated with anti-viral drugs; viremia resolved in all patients at a median of 24 days. Three patients were found to develop other bacterial and/or fungal infections following CMV viremia. Two of the seven patients died during 1-year follow-up, due to primary disease progression or Candida sepsis. None of the patients developed proven tissue-invasive CMV disease. The study did not evaluate the incidence of asymptomatic CMV infection/reactivation. Despite prior publications based on limited data, rituximab does not appear to contribute to an increased frequency of symptomatic CMV reactivation following ASCT.

KW - Autologous stem cell transplant

KW - Cytomegalovirus infection

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84969916542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969916542&partnerID=8YFLogxK

U2 - 10.1007/s00277-016-2700-4

DO - 10.1007/s00277-016-2700-4

M3 - Article

VL - 95

SP - 1323

EP - 1327

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 8

ER -